Compare OXM & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OXM | PRTC |
|---|---|---|
| Founded | 1942 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.9M | 464.3M |
| IPO Year | N/A | N/A |
| Metric | OXM | PRTC |
|---|---|---|
| Price | $38.00 | $17.46 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $44.80 | N/A |
| AVG Volume (30 Days) | ★ 294.4K | 3.9K |
| Earning Date | 03-26-2026 | 08-28-2025 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $1,493,854,000.00 | $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.68 | N/A |
| P/E Ratio | ★ N/A | $8.37 |
| Revenue Growth | N/A | ★ 1265.60 |
| 52 Week Low | $30.57 | $13.30 |
| 52 Week High | $75.89 | $20.00 |
| Indicator | OXM | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 45.00 |
| Support Level | $35.89 | $18.31 |
| Resistance Level | $41.60 | $18.98 |
| Average True Range (ATR) | 1.92 | 0.54 |
| MACD | 0.04 | -0.18 |
| Stochastic Oscillator | 42.88 | 5.75 |
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.